Formulation Development
Harpoon Therapeutics Presents Data on its TriTAC-XR Platform
Harpoon Therapeutics, Inc. recently presented a poster with preclinical data on its TriTAC-XR T cell engager platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, DC…..
Vaccitech’s VTP-300 Was Well-Tolerated & Induced T cells Against All Targeted HBV Antigens in Both Healthy Volunteers & Patients With Chronic HBV Infection in Interim Analyses
Vaccitech plc recently announced results from ongoing Phase 1 and Phase 1b/2a clinical trials of VTP-300, an immunotherapy candidate in development for the treatment of…
Oculis Announces Patient Dosing in its First Phase 3 Study for Investigational Topical Eye Drop Treatment for Diabetic Macular Edema
Oculis S.A. recently announced the first patients have been dosed in its Phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in Diabetic…
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination With Ipilimumab Shows Evidence of Direct Tumor Necrosis & Promising Overall Survival Results in Adult Subjects With Metastatic Sarcomas
Intensity Therapeutics, Inc. recently announced that data from its open-label Phase 1/2 study of novel lead asset, INT230-6, as a monotherapy or in combination with ipilimumab in…
Oncorus Announces Exclusive Licensing Agreement With Gaeta Therapeutics for Use of Locally Delivered Interleukin-12 Via Oncolytic Viral Expression in Combination With Immune Checkpoint Inhibitors
Oncorus, Inc. recently announced it has signed an exclusive licensing agreement with Gaeta Therapeutics Ltd., related to the use of locally delivered Interleukin-12 (IL-12) via…
Exavir Therapeutics Announces Preclinical Data Demonstrating Complete Elimination of HIV From Human Cells With LNP-Delivered Tat-Targeted CRISPR-Cas9
Exavir Therapeutics recently announced the publication of preclinical data for XVIR-TAT, Exavir’s proprietary gene editing program in early preclinical development as a potential cure for…
Finch Therapeutics Announces Positive Topline Data From Phase 2 PRISM-EXT Open-Label Study of Microbiome Therapy for Recurrent C. diff.
Finch Therapeutics Group, Inc. recently announced positive topline results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase 2 placebo-controlled trial evaluating CP101 for…
Mustang Bio Announces Exclusive Worldwide License Agreement With Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy With Curative Potential for RAG1 Severe Combined Immunodeficiency
Mustang Bio, Inc. recently announced that the company has executed an exclusive license agreement with Leiden University Medical Centre (LUMC) for a first-in-class ex vivo lentiviral gene therapy for the….
Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients With Parkinson’s Disease
Yumanity Therapeutics recently reported its lead product candidate, YTX-7739, in development for the treatment of Parkinson’s disease, achieved its primary endpoints in a randomized, placebo-controlled…
CN Bio & iiCON Announce COVID-19 Research Collaboration
CN Bio recently announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D program, to validate the next-generation of…
Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan
Rain Therapeutics Inc. recently announced its plan to commence a Phase 2 clinical trial, named MANTRA-3, evaluating the efficacy of milademetan, an oral mouse double…
Synlogic & Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria
Synlogic, Inc. and Ginkgo Bioworks recently announced the nomination of SYNB1353, an investigational Synthetic Biotic medicine for the treatment of homocystinuria (HCU). SYNB1353 is the…
Eton Pharmaceuticals & Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA Oral Solution
Eton Pharmaceuticals, Inc and Azurity Pharmaceuticals, Inc. recently announced the US FDA has approved EPRONTIA (topiramate) oral solution, 25 mg/mL. EPRONTIA has been approved as…
Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity Against Human Common Coronaviruses, Noroviruses, Rhinoviruses & Enteroviruses
Cocrystal Pharma, Inc. recently announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses…
TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients
TFF Pharmaceuticals, Inc. recently announced the completion of dosing in the Phase 1b clinical trial of Voriconazole Inhalation Powder (TFF VORI), a next-generation, direct-to-lung, inhaled…
PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate & Breast Cancers From National Cancer Institute
PDS Biotechnology Corporation recently announced a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary tumor-associated and immunologically active…
PDC* line Pharma Opens Last Cohort of PDC-Lung-101 Clinical Trial
PDC*line Pharma recently announced the last cohort of patients has been opened and the first patients were dosed, in the PDC-LUNG-101 Phase 1/2 clinical trial (NCT03970746) with PDC*lung01, the company’s therapeutic cancer….
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
Longeveron Inc. recently announced the selection of Biorasi LLC as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B…
Nemera Reinforces its Value Proposition With a Refreshing Visual Identity
More modern, our new brand identity truly embodies who we are, how we partner with our customers and ultimately the value we bring to millions…
XOMA Earns $35-Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer
XOMA Corporation recently announced NIS793, an anti-TGFβ monoclonal antibody licensed from the company, has advanced to the Phase 3 development stage, triggering a $35-million milestone…
